Unum Therapeutics (NASDAQ:UMRX) released its quarterly earnings data on Monday. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.31), Bloomberg Earnings reports. The business had revenue of $2.22 million during the quarter, compared to analysts’ expectations of $2.45 million.
Unum Therapeutics opened at $10.84 on Wednesday, Marketbeat Ratings reports. Unum Therapeutics has a 1 year low of $10.25 and a 1 year high of $10.76.
Several research firms have issued reports on UMRX. Wedbush reiterated an “outperform” rating and issued a $18.00 price objective on shares of Unum Therapeutics in a research report on Tuesday. Cowen began coverage on Unum Therapeutics in a research report on Monday, April 23rd. They issued a “market perform” rating for the company. SunTrust Banks began coverage on Unum Therapeutics in a research report on Monday, April 23rd. They issued a “buy” rating and a $21.00 price objective for the company. Finally, Morgan Stanley began coverage on Unum Therapeutics in a research report on Monday, April 23rd. They issued an “overweight” rating and a $20.00 price objective for the company.
In other news, Director Liam Ratcliffe purchased 550,000 shares of the company’s stock in a transaction dated Tuesday, April 3rd. The stock was acquired at an average price of $12.00 per share, for a total transaction of $6,600,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Venture Fund Ix L.P. Atlas purchased 94,052 shares of the company’s stock in a transaction dated Tuesday, April 3rd. The stock was purchased at an average price of $12.00 per share, with a total value of $1,128,624.00. The disclosure for this purchase can be found here.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.